# aTYR PHARMA INC: overview ATYR · Nasdaq · CIK 1339970 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/atyr.md) · [Financials](/companies/atyr/financials.md) · [Filings](/companies/atyr/filings.md) · [Insiders](/companies/atyr/insiders.md) Latest reported revenue: [$0](/filings/0001339970-26-000008.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001339970-26-000008). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001193125-25-269587.md) | [0.0 d](/filings/0001339970-26-000008.md) | [0.0](/filings/0000950170-25-065640.md) | [0.0](/filings/0001339970-25-000009.md) | [0.2](/filings/0001193125-25-269587.md) | [0.0 d](/filings/0001339970-26-000008.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(14076.3%)](/filings/0001193125-25-269587.md) | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | [(13549.5%)](/filings/0001193125-25-269587.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.23)](/filings/0001193125-25-269587.md) | not reported | [(0.17)](/filings/0001339970-26-000033.md) | [(0.22)](/filings/0001339970-26-000053.md) | [(0.26)](/filings/0001193125-25-269587.md) | not reported | [(0.11)](/filings/0001339970-26-000033.md) | [(0.11)](/filings/0001339970-26-000053.md) | | Free cash flow | $m | [(13.2) d](/filings/0001193125-25-269587.md) | [(13.2) d](/filings/0001339970-26-000008.md) | [(15.4)](/filings/0001339970-26-000033.md) | [(13.9) d](/filings/0001339970-26-000053.md) | [(20.5) d](/filings/0001193125-25-269587.md) | [(12.2) d](/filings/0001339970-26-000008.md) | [(12.7)](/filings/0001339970-26-000033.md) | [(9.4) d](/filings/0001339970-26-000053.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0000950170-24-031584.md) | [10.4](/filings/0000950170-25-038888.md) | [0.4](/filings/0001339970-26-000008.md) | [0.2](/filings/0001339970-26-000008.md) | [0.2](/filings/0001339970-26-000008.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(446.8%)](/filings/0000950170-25-038888.md) | [(15557.8%)](/filings/0001339970-26-000008.md) | [(28899.6%)](/filings/0001339970-26-000008.md) | [(40856.3%)](/filings/0001339970-26-000008.md) | | Net margin | % | not reported | [(436.5%)](/filings/0000950170-25-038888.md) | [(14274.5%)](/filings/0001339970-26-000008.md) | [(27243.8%)](/filings/0001339970-26-000008.md) | [(39009.5%)](/filings/0001339970-26-000008.md) | | Diluted EPS | $ per share | [(1.77)](/filings/0000950170-24-031584.md) | [(1.60)](/filings/0000950170-25-038888.md) | [(0.94)](/filings/0001339970-26-000008.md) | [(0.86)](/filings/0001339970-26-000008.md) | [(0.80)](/filings/0001339970-26-000008.md) | | Free cash flow | $m | [(33.3)](/filings/0000950170-24-031584.md) | [(43.5)](/filings/0000950170-25-038888.md) | [(37.4)](/filings/0001339970-26-000008.md) | [(69.2)](/filings/0001339970-26-000008.md) | [(62.1)](/filings/0001339970-26-000008.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/atyr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $5.1m | 8,509,678 | | Reduced −2,000,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.3m | 3,808,091 | | Reduced −4,041 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $1.6m | 2,610,548 | | Added +2,114,530 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.5m | 2,471,418 | | Reduced −12,235,425 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.1m | 1,827,332 | | Reduced −4,616,572 | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $1.1m | 1,788,167 | | New +1,788,167 | | [Kalehua Capital Management LLC](/funds/2106181.md) | 2026-06-30 | $1.1m | 1,788,167 | | New +1,788,167 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.0m | 1,721,297 | | Added +1,672,795 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $914.1k | 1,531,151 | | Reduced −2,336,062 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $801.9k | 1,343,636 | | Added +118,169 | ## Recent filings [All 733 filings](/companies/atyr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 09:03 ET | [8-K](/filings/0001339970-26-000071.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001339970-26-000071 | | 2026-10-16 | 16:02 ET | [8-K](/filings/0001339970-26-000068.md) | 5.07 Shareholder vote results | 0001339970-26-000068 | | 2026-09-24 | 07:47 ET | [8-K](/filings/0001339970-26-000065.md) | 8.01 Other events | 0001339970-26-000065 | | 2026-09-11 | 16:06 ET | [DEF 14A](/filings/0001339970-26-000061.md) | Proxy statement, period 2026-10-16 | 0001339970-26-000061 | | 2026-08-07 | 16:07 ET | [10-Q](/filings/0001339970-26-000053.md) | Quarterly report, period 2026-06-30 | 0001339970-26-000053 | | 2026-08-07 | 16:04 ET | [8-K](/filings/0001339970-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001339970-26-000051 | | 2026-07-31 | 16:44 ET | [8-K](/filings/0001339970-26-000042.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001339970-26-000042 | | 2026-06-08 | 16:04 ET | [8-K](/filings/0001339970-26-000039.md) | 3.01 Delisting notice | 0001339970-26-000039 | | 2026-06-01 | 16:04 ET | [8-K](/filings/0001339970-26-000036.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001339970-26-000036 | | 2026-05-15 | 16:01 ET | [10-Q](/filings/0001339970-26-000033.md) | Quarterly report, period 2026-03-31 | 0001339970-26-000033 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001339970-26-000008.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1339970 - Tickers: ATYR - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 09:04 ET. No prices; not investment advice.